Development and progression of cancer are mediated by alterations in transcriptional networks, resulting in a disturbed balance between the activity of oncogenes and tumor suppressor genes. Transcription factors have the capacity to regulate global transcriptional profiles, and are consequently often found to be deregulated in their expression and function during tumorigenesis. Sex-determining region Y-related high-mobility-group box transcription factor 4 (SOX4) is a member of the group C subfamily of the SOX transcription factors and has a critical role during embryogenesis, where its expression is widespread and controls the development of numerous tissues. SOX4 expression is elevated in a wide variety of tumors, including leukemia, colorectal cancer, lung cancer and breast cancer, suggesting a fundamental role in the development of these malignancies. In many cancers, deregulated expression of this developmental factor has been correlated with increased cancer cell proliferation, cell survival, inhibition of apoptosis and tumor progression through the induction of an epithelial-to-mesenchymal transition and metastasis. However, in a limited subset of tumors, SOX4 has also been reported to act as a tumor suppressor. These opposing roles suggest that the outcome of SOX4 activation depends on the cellular context and the tumor origin. Indeed, SOX4 expression, transcriptional activity and target gene specificity can be controlled by signaling pathways, including the transforming growth factor-b and the WNT pathway, as well as at the post-translational level through regulation of protein stability and interaction with specific cofactors, such as TCF, syntenin-1 and p53. Here, we provide an overview of our current knowledge concerning the role of SOX4 in tumor development and progression.
INTRODUCTION
The discovery of the sex-determining region Y (SRY) gene more than two decades ago revealed the existence of a family of evolutionary conserved SRY-related high-mobility-group (HMG)-box (SOX) transcription factors, characterized by their high degree of sequence homology with the SRY HMG DNA-binding domain. 1 To date, 20 members of this family have been identified in vertebrate species, which in mammals are subdivided into eight groups (A-H), of which most are represented by a single gene in invertebrates.
1 SOX family members are critical for many developmental processes regulating both the maintenance of stem cells and controlling terminal differentiation of a wide variety of cell types. 2 Consequently, deregulation and mutation of SOX genes have been implicated in a variety of hereditary human diseases and several SOX members have been demonstrated to be involved in tumorigenesis, such as SOX9 in breast cancer and SOX18 in prostate cancer. 2, 3 At the time of its discovery more than 15 years ago by Clevers and co-workers, 4 SOX4 was recognized as the first 'classical' transcription factor within the SOX family composed of separate DNA-binding and transactivation domains, functioning as a transcriptional activator in lymphocytes. Subsequently, SOX4 was demonstrated to be critical for cardiac outflow tract development and the differentiation of pro-B and T cells. 5, 6 More recent studies have identified SOX4 mRNA as one of the most frequently upregulated transcripts in a wide variety of human cancers, including prostate, colorectal and breast cancer (Table 1) . 7 Correspondingly, SOX4 has been recognized as one of the 64 'cancer signature' genes, suggesting a fundamental role in tumor development. 7 Nevertheless, many aspects of SOX4 function remain undefined or imperfectly understood. Here, we will discuss the molecular mechanisms regulating SOX4 functionality and discuss our current understanding concerning the role of this transcription factor in development, differentiation and cancer.
SOX4 DOMAIN STRUCTURE AND FUNCTION
SOX4 belongs to the highly conserved group C SOX (SOXC) transcription factors, which consists of two additional members: SOX11 and SOX12.
1 SOXC members are single exon genes, grouped on the basis of the high degree of sequence similarity in the HMG domain located at the N-terminal half of the protein, and are further distinguished from other SOX transcription factors by their conserved C-terminal transactivation domain (TAD) 8 ( Figure 1 ). Outside these two conserved domains, the homology between SOXC members is relatively low.
The SOX4 HMG domain (amino acids (aa) is responsible for DNA binding and DNA bending. 4, 9 It binds with high affinity to the minor groove of the heptamer DNA motif AACAAAG, with the optimal 10 bp sequence containing 5 0 AG and 3 0 G nucleotides directly adjacent to the core sequence. 4, 10, 11 The elucidation of the solution structure of the SOX4 HMG domain identified an L-shaped structure consisting of three a-helices connected by loop structures, which are stabilized by a highly conserved hydrophobic core. 12 Binding of the HMG domain to the minor groove in the DNA helix induces a sharp bend, altering local chromatin architecture and enabling the formation of functional transcriptional enhancer complexes. 9, [12] [13] [14] [15] The recently solved crystal structure of the SOX4 HMG domain in complex with DNA revealed slight structural differences in the DNA-binding interface of SOX4 compared with the previously identified structures of the HMG domains in SOX2 and SOX17. 16 This structural difference allows the SOX4 HMG domain to accommodate both a primary AACAAAG motif and a secondary AATTGTT motif. 16 The reported 62, 107 Medulloblastoma Significant increased expression compared with normal cerebellum. Trend toward prolonged patient survival with elevated SOX4 expression 99, [130] [131] [132] Prostate cancer SOX4 increased expression compared with normal prostate tissue. Increased levels of SOX4 expression correlate with more aggressive tumors and poor prognosis 59, 86, [133] [134] [135] Lung cancer Gene amplification of SOX4 at chromosome 6p in lung cancer cell lines and primary tumors. Ectopic SOX4 expression increases transforming ability in NIH-3T3 cells. SOX4 has been suggested as a lung tumor vaccine antigen 87, [135] [136] [137] Colorectal cancer High levels of SOX4 in microsatellite stable stage II cancers correlate with recurrence, linked to metastatic capacity of primary tumor 78, 79, 84 ACC Increased expression of SOX4 relative to normal tissue. Knockdown of SOX4 results in reduced viability and increased apoptosis. SOX4 contributes to malignant phenotype 58, 60 Bladder cancer Elevated SOX4 expression in bladder cancer compared with normal tissue. In high-grade urothelial carcinomas, the genomic segment 6p22 is amplified, resulting in increased expression of SOX4 100, 110, 111, 120, 138 Endometrial cancer SOX4 expression is significantly higher in tumor tissues compared with normal tissue; SOX4 is targeted by miRNA129-2, the expression of which is lost in endometrial cancer; hypermethylation of this miRNA is linked to poor overall survival 89 Glioblastoma multiforme SOX4 is upregulated in glioblastoma compared with the normal brain with especially high expression in the malignant glioma-initiating cells (cancer stem cells). Reduced expression of SOX4 abrogates tumorigenic activity 73, 74 Gallbladder carcinoma Elevated SOX4 overexpression in primary gall bladder carcinoma compared with normal epithelium of the gall bladder. SOX4 expression correlates with low-grade and better overall disease-free survival 102 Gastric cancer SOX4 is upregulated in gastric cancer compared with benign gastric tissue. SOX4 expression is inversely correlated with epigenetic silencing of miRNA129-2, which is associated with poor outcome 90 Breast cancer SOX4 expression is elevated in breast cancer compared with normal mammary tissue and positively correlates with tumor grade. SOX4 expression induces EMT and promotes metastasis in vitro and in xenograft models in vivo 63, 70, 114 Myeloma SOX4 is upregulated in myeloma cell lines and primary tumors. SOX4 is critical for the survival of CD56 þ myeloma cells 57 Pineoblastoma High expression levels of SOX4 compared with normal tissue 139 
Splenic marginal zone lymphomas
The SOX4 gene is a common retroviral integration site, and is associated with disease progression 43 Myeloid leukemia SOX4 is an oncogene in myeloid leukemia and is a common site for retroviral integration. SOX4 expression is increased in AML patient samples containing the AML-ETO1 translocation 41, 42, 44, 45, 48, 52 Uterine leiomyoma SOX4 overexpression compared with normal myometrium variation in binding motifs is in accordance with previous observations demonstrating a marked variability in the sequences bound by SOX4 in the promoters of its target genes, such as Tubulin-beta 3 (Tubb3) (TATTGTC, CATTGTG), Tead2 (CTTTGTC, CTTTGTT) and the AACAATA motif in the CD2 enhancer. 8, 17, 18 This variation in enhancer element sequence expands the repertoire of target genes regulated by SOX4.
Similar to other SOX transcription factors, the SOXC HMG domain has been demonstrated to interact with a variety of other transcription factors and thereby cooperatively regulate gene expression. 19 For example, SOX4 associates with BRN2 and TBX3, which results in synergistic activation of the Nestin gene in neurons and the Gja1 gene in the heart, respectively. 19 The transcription complexes formed upon binding distinct transcription factors represent an additional level of target gene specificity and transcriptional activation in a given cell system.
The C-terminal 33 residues in the SOX4 protein constitute the TAD. Deletion of this domain completely abrogates the transactivation capacity of SOXC members. 8 In SOX11, the TAD is predicted to adopt a stable uninterrupted a-helical structure, which is shorter and interrupted in SOX4 and SOX12. 8 Correspondingly, the SOX11 TAD possesses the strongest transactivating capacity followed by SOX4 and SOX12, respectively. 8 The mechanism through which the TAD of SOXC transcription factors controls transcriptional activation remains to be investigated. However, it is likely that the SOX4 TAD recruits coactivators, as the homologous domain in SOX2 has been demonstrated to recruit co-activators such as the histone acetyl transferase p300. 20 Interestingly, the TAD of SOX4 also controls proteasomal degradation and thereby regulates protein stability and expression. 21 In a variety of cancer cell lines, SOX4 was observed to be rapidly degraded by the proteasome, which was independent of polyubiquitination, but rather depended on the presence of the TAD. Proteasomal degradation could be prevented by association of the SOX4 TAD to its interaction partner syntenin-1, resulting in reciprocal stabilization in the nucleus and increasing the transcriptional output of SOX4. 21, 22 Two additional functional domains have been identified in SOX4: a glycine-rich region (aa 152-227), which was demonstrated to be involved in proapoptotic events, and a serine-rich region (aa 333-397), previously thought to be part of the TAD. 23 In addition to the functions detailed here, SOX4 domains can be the acceptor site for post-translational modifications (PTMs), modulating the functionality of these regions, and consequently SOX4 activity during development and tumorigenesis ( Figure 1 ). The role of context-dependent regulation of SOX4 will be discussed below.
SOX4 REGULATES EMBRYONIC DEVELOPMENT AND DIFFERENTIATION
To understand the role of SOX4 in malignancies, it is important to first highlight its role in normal vertebrate development and differentiation, as aberrant recapitulation of developmental processes in adult cells can underlie tumorigenesis. SOX4 expression is widespread during embryonic development, overlapping with other SOXC members in the central and peripheral nervous system, and mesenchyme of developing organs. 8, 24 In addition, SOX4 is expressed in the developing thymus, spleen, and hair follicles. 8 As suggested by its expression pattern, SOX4 has an important role in a plethora of developmental processes. Indeed, SOX4-deficient animals suffer from many developmental defects (Table 2) , resulting in lethality at embryonic day 14 (E14) as a result of circulatory failure caused by malformation of the cardiac outflow tract. 5 The late embryonic lethality can be attributed to the significant degree of redundancy between SOXC transcription factors. 25 High expression levels of all three SOXC genes are present in mesenchymal and neural progenitor cells, where they act redundantly to ensure survival of these multipotent cells. 8, 25 Consistent with their role in these cells, SOXC triple knockout mice die of severely impaired organogenesis at midgestation (E8).
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SOX4-deficient animals also suffer from defects in pancreatic islet formation, which results in impaired insulin secretion and glucose tolerance and models increased risk of type 2 diabetes and obesity in humans. [26] [27] [28] [29] In addition, loss of SOX4 during hematopoiesis blocks development of B cells at the pro-B-cell stage and severely affects the development of T lymphocytes, its activity playing an important role in mediating the transforming growth factor-b (TGF-b)-induced block in T-helper type 2 cell differentiation. 5, 6, 30 During hematopoiesis, SOX4 also controls differentiation of myeloid lineages regulated by the interleukin (IL)-5 receptor signaling complex, through direct interaction with the adaptor protein syntenin-1. 22, 31 Finally, mice that are heterozygous for the SOX4 knockout allele show diminished bone formation and osteoblast development, which is possibly due to SOX4-mediated effects on parathyroid and parathyroid-related hormone receptor signaling in osteoblast cells. 32, 33 Interestingly, in a genome-wide association study in humans the SOX4 locus has been associated with bone mineral density and fracture risk in postmenopausal women and reduced expression of SOX4 correlated with susceptibility to osteoporosis. 34, 35 After birth, expression of SOX4 becomes restricted as cells become terminally differentiated. In adult tissue, SOX4 expression appears to be more limited to specific cell types, including pancreatic islet cells, gonads, female reproductive tissues, thymus, hematopoietic stem cells, mammary stem cells and intestinal crypt stem cells. 4, [36] [37] [38] [39] [40] This restricted expression in adult tissues indicates that SOX4 activity has to be constrained to a limited subset of cells and potentially reflects the activity of various signaling pathways, controlling SOX4 expression and stability. The important developmental role of SOX4 in the control of cell fate and differentiation suggests that, similar to other tumor-related developmental transcription factors, aberrant regulation of SOX4 and associated developmental processes has a significant impact on tumorigenesis.
SOX4-MEDIATED REGULATION OF TUMORIGENESIS AND TUMOR PROGRESSION
In recent years, large-scale gene expression studies have been applied to identify novel cancer-related genes, which could be used as prognostic markers or therapeutic targets. Such studies have identified elevated SOX4 expression in nearly all major human cancers, including breast, lung, brain, prostate, colorectal, bladder, pancreatic and ovarian cancer, indicating a central role in the development of multiple tumors 7 ( Table 1) . Some of the most compelling evidence pointing towards a prooncogenic role for SOX4 originates from genome-wide retroviral tagging studies in cancers of hematopoietic origin. Retroviral insertional mutagenesis can result in activation of proto-oncogenes and more rarely inactivation of tumor suppressor genes, and tumor-promoting insertions are identified by their selective outgrowth. Such studies have identified SOX4 as the most common retroviral integration site in mouse myeloid leukemia, B/T-cell lymphomas and splenic marginal zone lymphomas (a B-cell lymphoma subset), indicating that, in addition to normal hematopoietic development, SOX4 can induce malignant hematopoietic development. [41] [42] [43] Indeed, forced expression of only SOX4 in mouse bone marrow cells is sufficient for cellular transformation by blocking myeloid differentiation and inducing the formation of myeloid leukemia in the majority of transplanted animals. 44, 45 Retroviral insertions in the SOX4 gene can also act synergistically with pre-existing or retrovirus-induced genetic lesions to promote development of myeloid leukemia, such as loss of Cdkn2a, Sfpi1 and p15Ink4b, proviral integration in the EVI1 oncogene, MADS box transcription enhancer factor 2C (Mef2C) and CREB, and viral integration of the large T antigen. 41, 44, [46] [47] [48] In a search for cooperating cancer genes, leukemias derived from SOX4-transduced bone marrow-transplanted mice were analyzed for insertional mutations induced by the SOX4 carrying retrovirus, revealing integrations in various cancer-related genes, including multiple integrations in the SfpiI (PU.1 in humans) gene and the Mef2C gene. 45, 49 The presence of multiple independent integrations at the loci of these important myeloid and lymphoid differentiation factors is indicative for a cooperative role with the introduced SOX4 oncogene. Indeed, co-transduction of bone marrow cells with Mef2C was shown to accelerate significantly the SOX4-mediated development of myeloid leukemia. 45 Similarly, haploinsufficiency of the SfpiI gene encoding the transcription factor PU.1 acted synergistically with SOX4 overexpression to promote murine myeloid leukemia. 50 In de novo tumors, SOX4 might actively repress SfpiI expression by directly binding an upstream regulatory element in the SfpiI gene, which is corroborated by an inverse correlation between SOX4 and PU.1 expression in acute myeloid leukemia (AML) patient samples. 50 In AML, SOX4 also acts in a cooperative manner with the proto-oncogenic transcription factor CREB to promote myeloid transformation by increasing cell survival and self-renewal.
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SOX4 was shown to directly regulate the expression of CREB by binding to an upstream CREB promoter element and inducing transcription. Accordingly, SOX4 and CREB protein expression were observed to be elevated and positively correlated in pediatric AML patient samples. 51 Increased expression of SOX4 in human AML also occurs in patient samples containing the common MOZ-TIF2, AML1-ETO and NUP98-HOXA9 translocations. [52] [53] [54] These findings indicate that SOX4 acts as a proto-oncogene in both myeloid leukemia and lymphomas by acting in concert with a variety of distinct genetic lesions.
Many oncogenic transcription factors in myeloid leukemias influence hematopoietic stem cell (HSCs) development and the induction or maintenance of leukemic stem cells. 55, 56 Also, SOX4 has been recognized as a potential regulator of HSC activity in both mouse and human hematopoiesis. 38 In a gain-of-function screen in mouse HSCs, SOX4 was identified as one of the 18 factors conferring increased HSC activity, demonstrated by increased repopulating capacity of the transduced HSCs. 38 Moreover, in a recent study using gene expression profiling to investigate transcriptional networks in isolated human hematopoietic cells, SOX4 and the known HSC-related transcription factor PBX1 were identified as key regulators of an HSC and progenitor gene expression profile. 56 This suggests a fundamental role for SOX4 in HSC development and maintenance, which could be mirrored by similar functions in leukemic stem cells. Nevertheless, the mechanisms whereby SOX4 functions in human HSCs or causality in the development of human myeloid leukemia remain unresolved. In addition, in multiple myeloma, a distinct hematological malignancy of the B-cell lineage, SOX4 expression has been linked to the expression of the neural cell adhesion molecule (NCAM/CD56).
57 SOX4 directly regulates expression of this neuronal marker, the expression of which occurs in the majority of multiple myelomas and is associated with tumor development, lytic bone lesions and poor disease prognosis, suggesting that SOX4 contributes to the development of CD56 þ multiple myelomas. 57 Taken together, it appears that deregulation of SOX4 during hematopoiesis has the capacity to give rise to distinct hematopoietic malignancies. However, it remains to be investigated how genetic alteration or aberrant regulation of SOX4 contributes to the development of hematopoietic tumors in humans.
Elevated expression of SOX4 has also been demonstrated in a wide variety of solid tumors (Table 1) . However, in contrast to hematological malignancies, disparate functions for SOX4 have been reported in the development and progression of solid tumors. In a manner reminiscent of c-MYC, SOX4 may act as either a tumor suppressor gene or oncogene, depending on the type of tumor, the cellular context and the stage of tumor development.
PRO-ONCOGENIC ROLES OF SOX4 IN SOLID MALIGNANCIES
There is compelling evidence to suggest that SOX4 acts as a protooncogene in a wide variety of solid tumors. Increased expression of SOX4 has been correlated with tumor development or tumor progression in colorectal cancer, breast cancer, prostate cancer, hepatocellular carcinoma (HCC), glioma, gastric cancer, adenoid cystic carcinoma (ACC), lung cancer and endometrial cancer (Table 1) . Depending on the tumor type, SOX4 expression may impact on a variety of distinct processes, including inhibition of apoptosis, increased cell invasion and metastasis, and induction and maintenance of cancer-initiating cells. 
Role of SOX4 in tumorigenesis and metastasis SJ Vervoort et al
Contribution of SOX4 to tumor initiation by inhibition of apoptosis and stimulation of cell proliferation and cell survival Similar to its prosurvival role in mesenchymal and neural progenitor cell development, several studies have provided evidence that SOX4 promotes tumorigenesis primarily through inhibition of apoptosis and stimulation of cell survival. SOX4 expression is distinctly higher in primary ACC and prostate tumors compared with the corresponding healthy tissue. [58] [59] [60] RNA interference-mediated downregulation of SOX4 in ACC-, prostate-and breast cancer-derived cell lines induced apoptotic cell death in vitro, suggesting that SOX4 contributes to cell survival. 59, 60 The prosurvival function of SOX4 could be related to its transcriptional regulation of the transcription factor TEAD2, which is part of the HIPPO signaling pathway and confers SOX4-mediated survival signals during organogenesis. Interestingly, the prosurvival role of the HIPPO pathway has also been implicated in the development and metastasis of a large variety of tumors, suggesting that SOX4-mediated modulation of this pathway may, in part, underlie its prosurvival function. 61 In addition to this prosurvival function, stable expression of SOX4 in non-transformed prostate cells was sufficient to confer oncogenic properties as illustrated by the increased colonyforming capacity in soft agar and anchorage-independent growth, suggesting that SOX4 exerts additional pro-oncogenic effects. 59 Promoting tumor progression through expansion of cancer stem cells, initiation of an epithelial-to-mesenchymal transition and tumor metastasis In addition to its role in the initial stage of tumor development, SOX4 can contribute to tumor progression by supporting expansion of highly aggressive tumor-initiating cells and by promoting tumor cell metastasis. In HCC and breast cancer, SOX4 mRNA expression has been demonstrated to be particularly elevated in metastases, which was associated with disease progression, recurrence and poor-metastasis-free survival. 62, 63 SOX4 has been demonstrated to function as an oncogene in more advanced stages of HCC by promoting intrahepatic metastasis. 62 Depletion of SOX4 in invasive HCC cell lines greatly suppresses in vivo tumor growth, invasion into smooth muscle layers and formation of metastatic tumor foci. Moreover, SOX4 knockdown in HCC cell lines was associated with distinct morphological changes in vitro, including reduced vimentin expression and altered actin organization. This phenotype resembles a reversion of the metastasis-associated mesenchymal phenotype to an epithelial state, a process that is termed the mesenchymal-toepithelial transition (MET). This suggests that SOX4 is involved in the promotion of an epithelial-to-mesenchymal transition (EMT) during metastatic conversion of HCC cells. 64 Using a bioinformatics approach combined with chromatin immunoprecipitation and SOX4 knockdown, 31 potential SOX4 target genes were identified in HCC. 62 Two of these genes, neuropilin-1 (NRP-1) and semaphorin 3C (SEMA3C), have previously been linked to tumor development and are part of a signaling pathway that regulates axonal guidance. Notably, this process is often aberrantly used by tumors to promote metastasis. [65] [66] [67] [68] Subsequently, SEMA3C and NRP1 were demonstrated to be potential effectors of the SOX4-induced metastatic phenotype, as knockdown of these genes in HCC cells reduced cell migration and invasion. This suggests that the metastatic potential of HCC cells is at least, in part, modulated through SOX4-mediated regulation of metastatic effectors.
Recently, SOX4 has been demonstrated to induce EMT in human mammary epithelial cells. Ectopic expression of SOX4 in these cells induced a mesenchymal phenotype, which was associated with increased stem cell properties, cellular migration and invasion in vitro.
69 SOX4 expression itself was shown to be regulated by TGF-b, a potent inducer of EMT in a variety of cancers. Importantly, in mammary epithelial cells, SOX4 was demonstrated to be required for TGF-b-mediated induction of EMT. Moreover, ectopic expression of SOX4 in mammary epithelial cells was sufficient to induce EMT and confer metastatic properties in vitro such as increased migration and enhanced stem cell properties. In mouse xenograft experiments, SOX4 potentiated RASinduced tumorigenesis in MCF10A cells and has also been shown to reduce the metastatic potential of highly metastatic derivatives of MDA-MB-231 cells. 63, 70 Moreover, immunohistochemical analysis of SOX4 expression in patient breast cancer samples revealed a positive correlation with tumor-grade and triple-negative breast cancers. 69 These findings demonstrate an important role for SOX4 in the progression and metastasis of high-grade breast cancers.
A role for SOX4 in the maintenance of cancer-initiating cells has been described in glioma, a tumor type that arises from glial cells in the brain or the spine. SOX4 expression is responsive to TGF-b in a variety of cell types, including highly aggressive glioma-initiating cells. In glioma-initiating cells, SOX4 expression is directly induced by SMAD2/3 downstream of TGF-b signaling. [71] [72] [73] [74] Subsequently, SOX4 induces the expression of the stem cell marker SOX2 through cooperative binding with OCT-4 to the SOX2 promoter, which was shown to be critical for TGF-b1-mediated maintenance of stemness in glioma-initiating cells. 74, 75 As SOX4 is found to be highly expressed in stem cells and early progenitors from a variety of tissues, it is possible that the stemness-promoting activity of SOX4 observed in glioma-initiating cells contributes to tumor progression in diverse malignancies.
Taken together, these data indicate that tumor-specific increased expression of the developmental transcription factor SOX4 contributes to tumor development and progression. Although this idea is heavily supported by the evidence reviewed here, the proposed mechanisms through which SOX4 exerts this pro-oncogenic function are diverse and appear to vary greatly depending on the tumor type.
SOX4 and the WNT/b-catenin signaling pathway The canonical WNT signaling pathway, which signals through bcatenin and TCF transcription factors, is critical for correct embryonic development and the maintenance of adult stem cells. Unsurprisingly, aberrant regulation of this pathway has been implicated in the pathogenesis of a wide variety of malignancies.
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SOX4 expression is upregulated by WNT signaling in both benign and malignant intestinal tissues. 37, 77, 78 In the intestine, SOX4 is predominantly expressed in the part of the crypt containing the intestinal stem cell compartment. 37 Although SOX4 has not been functionally implicated in the development or maintenance of these cells, SOX4 has been demonstrated to potentiate canonical WNT signaling through a variety of mechanisms. First, SOX4 directly interacts with TCF and b-catenin, which stabilizes the bcatenin/TCF complex. This results in increased WNT target gene activation and subsequently proliferation of colon carcinoma cells. 79, 80 Second, it has been proposed that SOX4 can stabilize b-catenin by transcriptional induction of casein-kinase 2, which is known to directly phosphorylate b-catenin, thereby protecting it from degradation. 80, 81 Third, SOX4 has been proposed to promote WNT/b-catenin signaling in endometrial carcinomas through direct transcriptional activation of TCF4 expression, resulting in WNT target gene activation. 82 Finally, SOX4 has been described to interact, in a WNT3a-dependent manner, with the E-cadherin and the desmosome-associated junction protein plakoglobin. 83 WNT3a-induced nuclear shuttling of junction protein plakoglobin increases the interaction with SOX4 and competes with the binding of SOX4 to b-catenin, resulting in nuclear export of SOX4 and reduction in the activity of WNT signaling pathway 83 ( Figure 2 ). Consistent with a role as an 'enhancer' of WNT signaling, increased SOX4 expression in colorectal cancer correlates with poor outcome. 84 Taken together, these findings indicate an important role for SOX4 in the WNT signaling pathway and WNT-driven colorectal tumorigenesis. In addition to colorectal cancer, aberrant WNT signaling has been implicated in the development of a large number of distinct human cancers, such as melanoma, breast cancer and leukemia. 85 However, it remains to be determined whether SOX4 contributes to WNTdriven tumorigenic effects in these cancers.
SOX4-mediated transcriptional regulation
As SOX4 is a transcription factor, its function in cancer most likely relies on its direct regulation of transcriptional target genes. A number of studies have investigated SOX4-mediated regulation of transcriptional targets in a variety of human cancers. Analysis of potential SOX4 target genes in prostate cancer, ACC, HCC and lung cancer revealed that SOX4 could be involved in the regulation of many key cellular processes, including apoptosis, cell cycle control, microRNA (miRNA) processing, differentiation and growth factor signaling. 59, 60, 62, 86 In lung tumors and cell lines, SOX4 expression is elevated because of genetic amplification of the SOX4 locus. 87 Based on this tumor-specific expression of SOX4 in lung tumors and the presence of naturally occurring SOX4 antibodies in small-cell lung cancer patients, SOX4 has been considered as a possible antigen for lung tumor vaccination. 80 SOX4 knockdown in lung cancer cells carrying a SOX4 amplification was demonstrated to result in differential expression of numerous genes involved in neuronal development, such as TEAD2, the PCDHB gene cluster, MYB and RBP1. 88 The SOX4 gene signature in lung cancer was particularly prominent in small-cell lung cancer, which is characterized by its neuroendocrine nature and elevated expression of SOX2, SOX4 and SOX11. 88 Investigation of direct transcriptional targets of SOX4 in the prostate cancer cell line LNCaP, using chromatin immunoprecipitation-based genome-wide promoter binding analysis and microarray gene expression profiling, revealed SOX4-mediated regulation of genes involved in WNT signaling, inflammation and apoptosis 59, 86 A large number of genes were characterized as direct targets based on SOX4 promoter binding combined with altered gene mRNA transcript levels upon modulation of SOX4 expression by either knockdown or overexpression. The set of proposed direct transcriptional targets consists of important cancer-related genes, including EGFR, DICER, Tenascin C, ADAM10 and Frizzled-5, regulating miRNA processing, embryonic development, growth factor signaling and tumor metastasis. 86 Microarray analysis of SOX4 knockdown in ACC cells revealed differential expression of genes involved in cell cycle and apoptosis pathways, including BIRC5, BNIP3 and Cyclin-B1, suggesting that in both prostate cancer and ACC increased tumor-specific SOX4 expression activates a variety of pro-oncogenic pathways through the induction of SOX4 target genes. 60 However, the functional contribution of individual target genes to the SOX4-mediated tumorigenic responses remains to be determined. Similar to ACC and prostate cancer, SOX4 knockdown in gastric and endometrial cancer cell lines decreases proliferation and increases apoptosis. 89, 90 Taken together, these data suggest that SOX4 expression in a variety of diverse tumors promotes cell survival and transformation, through increased proliferation and inhibition of apoptosis.
Although several studies have attempted to identify SOX4 transcriptional targets in human tumors, comparative analysis of SOX4 transcriptional targets between cancers types reveals a relatively minor degree of overlap (Figure 3a) . Although the limited overlap could be the result of limitations in the different experimental setups, it is more likely that it rather reflects tumorspecific and context-dependent mechanisms in target gene selection. In agreement with this is the finding that the core SOX4-regulated genes, such as the tyrosine kinase signalingassociated EGFR and VEGF, are present in multiple studies (Figure 3b) . Notably, EGFR and VEGF are well known for their pivotal role in the development of cancer by regulating cellular transformation and angiogenesis, respectively. 91, 92 In addition, other SOX4 targets within this group, such as SLCO5A1, CCNG2, GPR56, GRN, MGAT4B, SKP2, TRIB3 and CD24, have been demonstrated to have diverse roles in the tumorigenesis of a variety of cancers (Figure 3b) . [92] [93] [94] [95] [96] [97] [98] The context-dependent activation of target genes is reminiscent of other transcriptional effectors involved in signaling pathways such as the TGF-b pathway, in which the SMAD transcription factors elicit distinct responses in a cell-type-and tumor-stage-dependent manner. The consequences for TGF-b-induced tumor cell fate outcome are that in early-stage tumor development, the pathway acts in a tumorsuppressive manner, but promotes metastasis in more advanced tumors. The wide variety of target genes in different cell systems might suggest that this process is mirrored by SOX4.
TUMOR SUPPRESSOR FUNCTIONS OF SOX4
In direct contrast to the tumor-and metastasis-promoting role of SOX4, several studies have shown that increased SOX4 expression correlated with prolonged patient survival and slower disease progression in a variety of cancers, including bladder cancer, colon carcinoma, HCC, melanoma and gallbladder cancer. [99] [100] [101] [102] This suggests that SOX4 in these malignancies can act as a tumor suppressor. In bladder cancer, colon carcinoma and HCC, the tumor-suppressive function of SOX4 has been attributed to its ability to induce apoptosis, which may occur downstream of various stimuli, including prostaglandins and DNA damage. 100, [103] [104] [105] [106] Inhibition of tumor initiation through DNA-damage signaling and activation of apoptosis SOX4 has been identified as an effector of the DNA-damage pathway, which is required for DNA-damage-induced activation of p53. 103 Upon treatment of the colon carcinoma cell line HCT116 with DNA-damage-inducing agents and subsequent activation of DNA-damage signaling through ATM/ATR kinases, SOX4 protein expression and stability were observed to be increased in an ATM/ ATR-dependent but p53-independent manner. 103, 104 This DNAdamage-induced increase in SOX4 expression was not associated with increased mRNA expression, suggesting a yet unknown posttranslational mechanism. 103, 104 In the presence of DNA damage, SOX4 also directly interacts with p53, resulting in increased expression of the latter through recruitment of p300/CBP to the SOX4-p53 complex. Subsequent acetylation of p53 disrupts binding to its ubiquitin ligase MDM2, thereby decreasing p53 polyubiquitination, inhibiting nuclear export and increasing p53 stability. 103 In support of these findings, SOX4 was demonstrated to induce apoptosis and cell cycle arrest in vitro, and impair tumor growth in vivo in a p53-dependent manner in HCT116 cells. 103 Similar to colon carcinoma, in primary HCC, SOX4 acts as a tumor suppressor by interacting with the DNA-damage pathway. Etoposide-mediated activation of the DNA-damage pathway in HCC cell lines has also been demonstrated to result in SOX4 stabilization and interaction with p53. 107 However, in contrast to previous findings, SOX4 overexpression decreased p53-mediated transcriptional activation of the proapoptotic BAX gene, and reduced p53-induced apoptosis upon DNA damage. 107 Nonetheless, increased SOX4 expression was observed to correlate with diminished risk of recurrence and improved overall survival in patients, suggesting a tumor-suppressive function. 107 These findings are in contrast with previous reports stating a metastasis-promoting function of SOX4 in advanced stages of HCC. 62 This apparent contrast could illustrate stagespecific effects of SOX4 in the context of HCC. While SOX4 may act as a tumor suppressor in the initial stages of the disease by promoting apoptosis, in more advanced stages of tumorigenesis, it may acquire metastasis-promoting capacity due to mutational inactivation of the DNA-damage pathway and activation of prometastatic genes. SOX4 has recently been suggested to have a role in the DNA-repair pathway upstream of p53 in medulloblastomas. In medulloblastoma cell lines, SOX4 expression was rapidly induced upon g-irradiation, a process that could be prevented by ectopic expression of the secreted protein acidic and rich in cysteine protein (SPARC), a glycoprotein that is involved in radiotherapy sensitization. 108 Ectopic SPARC expression as well as small interfering RNA-mediated SOX4 depletion resulted in decreased DNA repair and increased radiotherapy sensitivity which was associated with reduced p53 phosphorylation and increased DNA-damage, suggesting a potential role for SOX4 in the p53-mediated DNA-repair pathway. SOX4 mRNA expression has also been shown to be rapidly induced by treatment of HCT116 cells with the chemotherapeutic agents 5-fluorouracil and oxaliplatin, and its expression remained elevated in therapy-resistant cells compared with non-resistant parental lines. 109 These findings suggest that SOX4 has dual roles in cancer therapy treatment, promoting either resistance or sensitization depending on the cellular context and tumor type.
In bladder cancer, SOX4 has been suggested to function as a tumor suppressor in a manner independent of the DNA-damage pathway. In a number of bladder carcinoma cell lines, the genomic region 6p22.3, which harbors the SOX4 gene, is amplified, resulting in gene duplication. Although this copy number variation cannot be directly related to increased SOX4 expression, SOX4 mRNA and protein levels are significantly elevated in bladder carcinoma samples when compared with normal tissue, which correlates with prolonged patient survival. 100, 110, 111 Similar to HCC, increased expression of SOX4 in the HU609 bladder carcinoma cell line decreases cell viability and induces apoptosis. 100 The tumorsuppressive role of SOX4 in these cells appears to be related to activation of proapoptotic and antiproliferative SOX4 target genes. 100 Microarray analysis of HU609 cells, which overexpress SOX4, revealed differential expression of 130 potential SOX4 target genes, involved in angiogenesis, cell cycle arrest and apoptosis, such as interleukin-8, NEDD9 and PIK3R3. 100 A small subset of 27 genes also correlated with SOX4 expression in primary bladder tumors, suggesting that the majority might not represent direct target genes or that additional factors are 
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273 genes SOX4 knockdown Prostate cancer P r o s ta te c a n c e r L u n g c a n c e r CCNG2  RNF150  PCDHB5  SLCO5A1  MAN1C1  GPR56  GRN  MGAT4B  SKP2  VEGF  TRIB3  CD24 involved in their modulation. These findings indicate that the tumor-suppressive function of SOX4 can at least, in part, be explained by proapoptotic effects through interaction with the p53 DNA-damage pathway or through the induction of proapoptotic and antiproliferative SOX4 target genes.
Inhibition of tumor suppression by repressing tumor metastasis A recent study investigating the effects of SOX4 in human cutaneous melanoma revealed that the tumor-suppressive activities of SOX4 might also stem from its ability to regulate tumor cell migration and invasion. 101, 112 Ectopic SOX4 expression decreased melanoma cell migration, invasion and stress fiber formation through direct transcriptional repression of the prometastatic factor nuclear factor-kB p50. Markedly reduced expression of SOX4 was observed in metastatic melanoma compared with primary tumors, which inversely correlated with nuclear factor-kB p50 expression and was related to diminished patient survival. 101 In addition, SOX4-induced suppression of melanoma metastasis can be mediated by direct transcriptional regulation of DICER, a critical component of the miRNA processing pathway. 112 In patient samples, DICER expression positively correlated with SOX4 expression and reduced expression of DICER was linked to disease progression and decreased patient survival. 112 Moreover, in vitro knockdown of DICER increased melanoma invasion in matrigel and its overexpression was sufficient to revert the proinvasive phenotype of SOX4 knockdown melanoma cells. Interestingly, knockdown of SOX4 and the resulting decreased DICER expression greatly altered the melanoma miRNA profile, suggesting that changes in miRNA expression underlie the metastasis-suppressive role of SOX4 in melanoma. 112 Taken together, these studies suggest that, depending on the type of cancer and cellular context, SOX4 may function as a tumor suppressor, exerting its effects through the induction of apoptosis or inhibition of tumor metastasis.
CELLULAR CONTEXT MODULATES SOX4 EXPRESSION AND ACTIVITY
Context-dependent and tumor-specific effects of SOX4 can originate from underlying differences in the control of its mRNA expression and differential regulation of its protein stability and activity ( Figure 2 ).
Regulation of SOX4 mRNA expression SOX4 mRNA expression can vary greatly in a tumor-type-specific manner through amplification of the SOX4 locus and the concerted activity of signaling pathways and microRNAs. The SOX4 6p22 locus has been observed to be amplified in bladder and lung cancer, resulting in increased SOX4 expression in the latter. 87, 111, 113 Nevertheless, it remains to be determined whether amplification of the SOX4 locus occurs in a larger variety of human cancers and to which extent this contributes to the elevated expression of SOX4 in observed in human cancers.
Differential expression of SOX4 could also be related to the activity of a variety of signaling pathways, such as the previously mentioned TGF-b and WNT signaling pathways (Figure 2 ). In addition to TGF-b and WNT signaling, SOX4 expression is under the control of estrogen and progesterone in female reproductive tissues, as well as in normal and malignant breast tissue.
114 SOX4 expression is rapidly induced upon activation of the progesterone receptor, resulting in enhanced transcriptional activity. 114, 115 Interestingly, SOX4 activity in hormone-sensitive tissues has the potential to induce a positive feedback loop by regulating expression of the gonadotropin-releasing hormone (GnRH), which subsequently induces the release of estrogen and progesterone through follicle-stimulating hormone and luteinizing hormone. 116, 117 During normal development, estrogen and progesterone control the growth and differentiation of the mammary gland. However, both these hormones also profoundly influence the development of breast cancer. 118, 119 It is thus possible that, in the context of hormone-sensitive cancers such as breast cancer and ovarian cancer, the tumorigenic effects exerted by SOX4 depend on the expression and activation of the estrogen and progesterone receptors, providing an example of context-specific regulation, even between cancer subtypes.
Tumor-type-and stage-specific expression of SOX4 can also occur through miRNA-mediated regulation of mRNA stability and protein translation. In bladder cancer, genomic profiling of miRNAs revealed that expression of the SOX4 targeting miRNA-129 positively correlated with disease progression. The expression of miRNA-129 inversely correlated with SOX4 expression levels and was associated with poor outcome, suggesting that in the context of bladder cancer miRNA-mediated repression of SOX4 expression promotes tumor progression. 120 In contrast, loss of SOX4 targeting miRNAs in gastric cancer, endometrial cancer and breast cancer has been demonstrated to promote tumor progression. 63, 89, 90 In both endometrial and gastric cancer, SOX4 mRNA expression can be repressed by miRNA-129-2, the expression of which is frequently lost because of hypermethylation-mediated silencing, resulting in elevated SOX4 expression. 89, 90 In endometrial cancer, loss of miRNA-129-2 was demonstrated to promote cell proliferation and correlated with poor overall survival in patients, 89 whereas in gastric cancer, depletion of SOX4 through ectopic expression of miRNA-129-2 or small interfering RNA-mediated knockdown was shown to induce apoptosis. 90 It thus appears that miRNA-mediated regulation of SOX4 expression in gastric and endometrial cancer has an important role during tumorigenesis.
In a similar manner, SOX4 mRNA expression has been shown to be directly regulated through miRNA-335 in the breast cancer cell line MDA-MB-231. 63 The expression of miRNA-335 was lost in MDA-MB-231 derivative breast cancer cell lines, which readily metastasize to either lung or bone. 63 Ectopic expression of miRNA-335 or SOX4 knockdown in these highly metastatic MDA-MB-231 cells altered breast cancer cell morphology and decreased migration and invasion in vitro and significantly reduced metastatic foci in the lungs in vivo, suggesting that, in part, miRNA-335 exerts its antimetastatic effects through regulation of SOX4 expression. 63 In the breast cancer cell line SUM159, SOX4 has been demonstrated to be the target of miRNA-93, which is frequently overexpressed in a variety of human cancers and affects stem cell differentiation and proliferation in both normal mammary tissue and breast cancer. 121 Ectopic expression of miRNA-93 in a xenograft mouse model of breast cancer abrogated tumorigenesis and metastasis. Moreover, in SUM159 cells miRNA-93 was observed to promote MET and maintain an epithelial state by decreasing TGF-b signaling and the expression of stem cellrelated genes such as AKT3, EZH1 and SOX4 in vitro 121 Thus, miRNA-335-and miRNA-93-mediated modulation of SOX4 expression appears to influence breast cancer progression by affecting the generation of cancer stem cells, EMT and tumor metastasis. These findings indicate that elevated SOX4 expression might, in part, result from hypermethylation-mediated silencing of specific miRNAs, adding another level of complexity to the regulation of SOX4 mRNA expression.
Taken together, these findings indicate that context-dependent and tumor-specific mechanisms regulate SOX4 expression on a number of levels, suggesting that tight regulation of this transcription factor is important during development and that aberrant regulation may impact on various aspects of tumorigenesis.
Regulation of SOX4 protein expression and activity In addition to regulation of SOX4 on the mRNA level, modulation of SOX4 transcriptional activity and expression can occur through PTMs and protein-protein interactions. Despite the crucial role of post-translational regulation for the proper activation of most transcription factors, the knowledge about the regulation of SOX4 on this level remains limited. The SOX4 protein has a very short half-life, which potentially allows for the tight control of SOX4 protein levels. 21 The rapid turnover also indicates the requirement to evaluate SOX4 protein levels as post-translational regulation of protein expression could result in a large discrepancy between mRNA and protein expression. The rapid protein turnover of SOX4 is reminiscent of important transcriptional regulators such as p53 and MYC of which the protein expression is tightly controlled on the post-translational level. For several members of the SOX family of transcription factors, PTMs, including phosphorylation, acetylation and sumoylation, have been described to regulate protein expression, activity and localization. However, there is currently no direct evidence showing that the transcriptional activity of SOX4 is regulated in this manner. Nevertheless, it is likely that similar to other SOX family members, SOX4 activity is regulated through distinct PTMs. 122 Multiple SOX4 PTMs identified by mass spectrometry have been reported, although the function of these modifications remains to be determined (www.phosphosite.org) (Figure 1 ). 123 Transcriptional activity and target gene specificity of SOX4 is also controlled through cooperative interactions with distinct transcription factors and cofactors. Syntenin-1 has been identified as an important regulator of SOX4 protein stability and transcriptional activity. 21 Syntenin-1 interacts with a large variety of cell surface proteins, including interleukin-5 receptor, syndecans, ephrin and frizzled receptors, and its expression contributes to metastasis in breast cancer, gastric cancer and melanoma. 124, 125 Thus, syntenin-1-mediated regulation of SOX4 stability might contribute to tumorigenesis and metastasis. In addition, SOX4 has been shown to associate with the E2 ubiquitin-ligase Ubc9, which inhibits the transcriptional activation of SOX4 downstream of the progesterone pathway independent of its SUMO-1-conjugating activity.
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SOX4 also interacts with a number of transcription factors, including TCF and OCT-4, to synergistically activate target genes in colorectal cancer and glioma, respectively. 75, 79 In colon cancer, SOX4 has been shown to cooperate with the oncogenic transcription factor ETS-1 to promote transcription of the lymphocyte-specific protein tyrosine kinase, a gene which has been correlated with high recurrence of liver metastases. 126, 127 ETS-1 functions as a potent oncogene in a wide variety of tumors, including colorectal cancer, and it is possible that synergistic activation of shared SOX4/ETS-1 target genes contributes to tumor formation and metastasis. 128 This cooperative binding and activation of target genes appears to be a common feature within the SOX family of transcription factors, making it very likely that, yet to be identified, transcriptional partners of SOX4 contribute to its selection of its pro-or antitumorigenic target genes.
129
SOX4 transcriptional activity can also be determined by the mutational status of the cancer cell. It is possible that SOX4 itself is mutated, resulting in aberrant regulation and activity. Evidence to support this notion is present in lung tumors where deregulation of SOX4 occurs through tumor-specific acquired somatic mutations. 87 One mutation introduces a premature stop codon (S395X) in SOX4, which abrogates its transcriptional activity, but dramatically increases protein stability, which is consistent with findings that the C-terminal TAD domain regulates SOX4 proteasomal degradation. 21, 87 Interestingly, this SOX4 mutant acted in a dominant-negative manner on RHO-Q63L-and HRAS-G12V-induced transformation of NIH3T3 cells, whereas wild-type SOX4 promoted cellular transformation. In addition to mutations in SOX4, mutations in receptor signaling pathways and the DNAdamage pathway could affect SOX4-dependent processes. For example, the interaction between SOX4 and DNA-damage response pathway may be disrupted through frequently occurring mutations in p53, resulting in contrasting effects of SOX4 activation on cell survival depending on the tumor type.
FUTURE PERSPECTIVES
From the time of its discovery, SOX4 has been demonstrated to be critical for numerous aspects of embryogenesis and various facets of tumorigenesis and tumor progression. In the development of human cancers, SOX4 has disparate roles acting as either a tumor suppressor or an oncogene and affects key processes related to tumor biology, including apoptosis, cell proliferation, migration, metastasis, EMT and cancer stemness. The opposite roles of SOX4 in these processes could be related to, yet unexplored, regulation of expression levels and protein activity of this transcription factor through transcriptional, post-transcriptional and post-translational events. This is influenced by cofactors, gene mutations, miRNAs and various signaling pathways, the cellular context and tumortype of which thus determines whether SOX4 acts as a friend or a foe. Nevertheless, although this dual role of SOX4 in tumorigenesis and progression has recently been appreciated, it warrants further investigation into its function and regulation.
Future insight into the regulation of SOX4 and its downstream target genes in the context of cancer development and progression could prove useful to design pharmacological compounds that modulate the activity of this important transcription factor. However, despite the prospective therapeutic benefits of such compounds, it is imperative to carefully assess the cellular context of the tumor and role of SOX4 herein to prevent adverse effects brought on by inhibition of its tumor-suppressive function.
